HOME >> BIOLOGY >> NEWS
Prenatal exposure to nicotine increases risk of apnea in brains of newborn rats

University of Arizona researchers report new evidence that exposure to nicotine in the developing rat fetus enhances the function of GABAa receptors, a key component of brain cells that control breathing rhythm. The increased functional capacity of the GABAa receptors may make these newborns more likely to have episodes of apnea, in which breathing simply stops.

Zili Luo, MD, Ph.D., a postdoctoral fellow in the laboratory of Dr. Ralph Fregosi, describes the study at the Experimental Biology 2003 meeting in San Diego, as part of the American Physiological Society program.

In humans, cases of Sudden Infant Death Syndrome (SIDS) occur most often in infants between the ages of two and four months, while the baby is sleeping. SIDS deaths usually are attributed to apnea or the cessation of breathing and the failure of the infant to self-resuscitate or resume breathing. Smoking during pregnancy has been found to increase the risk of Sudden Infant Death Syndrome (SIDS) by about five fold, and researchers have long been eager to pinpoint the mechanism by which this occurs.

Earlier studies by other investigators showed that prenatal nicotine exposure enhances the function and density of GABAa receptors in the cortex, hippocampus and other areas of the brain. These observations led the Fregosi laboratory to hypothesize that prenatal nicotine exposure may also alter the function or density of the GABAa receptors on cells in the brain regions that control breathing. In earlier work, the Fregosi laboratory had already sown that pharmacological stimulation of these inhibitory nerve cell membrane receptors led to slowing of the breathing rate, with intense stimulation leading to cessation of breathing altogether.

This study looked at whether prenatal nicotine enhances the function of these receptors, thus making it more likely that newborns that had been exposed to nicotine would have more episodes of apnea when the GABAa receptors are stim
'"/>

Contact: Sarah Goodwin
eb3press@bellsouth.net
770-270-0989
Federation of American Societies for Experimental Biology
12-Apr-2003


Page: 1 2 3

Related biology news :

1. Prenatal nicotine primes adolescent brain for addiction
2. Prenatal exposure to second-handsmoke greater for disadvantaged children, study finds
3. Study: Prenatal screening in Haiti region cut syphilis by 75 percent
4. Prenatal alcohol exposure can damage both information processing and response capabilities
5. Prenatal alcohol exposure affects visual processing
6. Just One Prenatal Visit Decreases Risk Of Preterm Delivery
7. Smokings Effects On Pregnancy Not Mitigated By Prenatal Vitamins, UB Study Finds
8. USC study links historical increases in life span to lower childhood exposure to infection
9. 9/11 search-and-rescue dogs exhibit few effects from exposure to disaster sites
10. Managing occupational exposures to potential bioterrorist agents
11. Infant rats eagerly accept high concentrations of alcohol upon first exposure

Post Your Comments:
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: